Picture1.png
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
08. Mai 2024 17:47 ET | Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
Picture1.png
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
08. Mai 2024 08:00 ET | Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
Picture1.png
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
07. Mai 2024 16:00 ET | Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel...
Picture1.png
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
16. April 2024 08:00 ET | Acumen Pharmaceuticals, Inc.
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany...
Picture1.png
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
04. April 2024 08:00 ET | Acumen Pharmaceuticals, Inc.
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the...
Picture1.png
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
26. März 2024 07:00 ET | Acumen Pharmaceuticals, Inc.
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease expected in the first half of 2024 Initiation of a Phase 1 study to...
Picture1.png
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
21. März 2024 08:00 ET | Acumen Pharmaceuticals, Inc.
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a...
Picture1.png
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
19. März 2024 16:00 ET | Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel...
Picture1.png
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
12. März 2024 16:00 ET | Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
Picture1.png
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
08. März 2024 08:50 ET | Acumen Pharmaceuticals, Inc.
- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug’s downstream pharmacological effects in the brain in early AD - Poster presentation showcases method used to develop...